Lupin receives tentative approval from USFDA for Raltegravir Tablets

This product will be manufactured at Lupin’s Nagpur facility in India

Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro

The company uses iPS cells to develop treatments for diseases relating to the kidney

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore

Lupin to develop inhalers with near-zero global warming potential propellants

Lupin's R&D teams are working on products with a near-zero global warming potential propellant

GlaxoSmithKline Pharmaceuticals Q2 FY25 revenue crosses Rs. 1,000 Cr

The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market

Lupin appoints Claus Jepsen as President, Global Specialty

AstraZeneca advances science of infectious disease protection at IDWeek 2024

Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19

Indian drug regulator recommends Wockhardt's Miqnaf for treatment of CABP

Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO

Emcure signs agreement with Gilead for manufacture and supply of Lenacapavir

Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries

Dr. Reddy’s signs licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir

Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022